Guardant Health Reports Q3 2026 Results and Raises Full-Year Revenue Guidance

Guardant Health, Inc. Q3 2026 Earnings & Operational Summary

Guardant Health, Inc. furnished its Q3 2026 financial results under Item 2.02 via Form 8-K on November 5, 2026.

Key Financial Highlights

• Total Revenue: $361.0 million, up 36% year-over-year compared to $265.2 million in Q3 2025.
  • Oncology Revenue: $231.3 million (+25% YoY); test volume reached 117,000 (+58% YoY).
  • Screening Revenue: $67.6 million (+180% YoY); Shield test volume reached 83,000 (+246% YoY).
  • Biopharma & Data Revenue: $59.0 million (+8% YoY).
  • Licensing and Other Revenue: $3.1 million vs. $2.0 million in Q3 2025.
• Gross Margin: GAAP gross margin was 65% (matching prior year period); Non-GAAP gross margin was 67% compared to 66% in Q3 2025.
• Operating Loss: GAAP operating loss of $(132.8) million compared to $(99.0) million in Q3 2025, driven by higher SG&A and commercial expansion.
• Net Loss: GAAP net loss of $(124.4) million ($(0.93) per share) vs. $(92.7) million ($(0.74) per share) in Q3 2025.
• Non-GAAP Net Loss: $(38.8) million ($(0.29) per share) vs. $(48.3) million ($(0.39) per share) in Q3 2025.
• Adjusted EBITDA: Loss of $(37.3) million vs. $(45.5) million in Q3 2025.
• Free Cash Flow: $(37.2) million burn vs. $(45.8) million in Q3 2025.
• Cash Position: Cash, cash equivalents, and restricted cash stood at $1.1 billion as of September 30, 2026.

Raised FY 2026 Guidance

• Full-Year Revenue: Increased to $1.36 billion–$1.37 billion (growth of 38% to 40%), up from previous guidance of $1.34 billion–$1.36 billion.
• Screening Revenue: Projected at $233 million–$238 million on 285,000–290,000 Shield tests (raised from $218M–$230M and 270,000–285,000 tests).
• Non-GAAP Gross Margin: Expected to be approximately 65%.
• Non-GAAP Operating Expenses: Guided to $1.105 billion–$1.125 billion.
• Free Cash Flow Burn: Forecast between $205 million and $220 million.